This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Banerjee, S. Articles by Banerjee, S. K. Search for Related Content PubMed PubMed Citation Articles by Banerjee, S. Articles by Banerjee, S. K.

CCN5/WISP-2 Expression in Breast Adenocarcinoma Is Associated with Less Frequent Progression of the Disease and Suppresses the Invasive Phenotypes of Tumor Cells

¹ Cancer Research Unit, Veterans Affairs Medical Center, Kansas City, Missouri and ² Division of Hematology and Oncology, Department of Medicine, and Department of Pathology, ³ Breast Cancer Prevention Center, and ⁴ Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas

Requests for reprints: Sushanta K. Banerjee, Cancer Research Unit, Research Division, Veterans Affairs Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128. Phone: 816-861-4700, ext. 57057; Fax: 816-922-3320; E-mail: sbanerjee2{at}kumc.edu.

Key Words: CCN5/WISP-2 • breast cancer progression • migration • invasive phenotypes

Although previous in vitro studies predicted that CCN5/WISP-2 may act as an anti-invasive gene in breast cancer, the distribution pattern of CCN5 in breast cancer samples is conflicting. Thus, we systematically investigated the CCN5 expression profile in noninvasive and invasive breast tumor samples and its functional relevance in breast cancer progression. The studies showed that CCN5 expression is biphasic, such that in normal samples CCN5 expression is undetectable, whereas its expression is markedly increased in noninvasive breast lesions, including atypical ductal hyperplasia and ductal carcinoma in situ. Further, CCN5 mRNA and protein levels are significantly reduced as the cancer progresses from a noninvasive to invasive type. Additionally, we showed that CCN5 mRNA and protein level was almost undetectable in poorly differentiated cancers compared with the moderately or well-differentiated samples and its expression inversely correlated with lymph node positivity. The result was further supported by evaluating the RNA expression profile in microdissected sections using real-time PCR analysis. Therefore, our data suggest a protective function of CCN5 in noninvasive breast tumor cells. This hypothesis was further supported by our in vitro studies illuminating that CCN5 is a negative regulator of migration and invasion of breast cancer cells, and these events could be regulated by CCN5 through the modulation of the expression of genes essential for an invasive front. These include Snail-E-cadherin signaling and matrix metalloproteinase (MMP)-9 and MMP-2. Collectively, these studies suggest that the protective effect of CCN5 in breast cancer progression may have important therapeutic implications. [Cancer Res 2008;68(18):7606–12]